IQVIA Veeva clinical operations collaboration expanded on October 13, 2026, when IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) announced the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications. These applications will be used across IQVIA clinical development studies. The announcement was issued from Research Triangle Park, North Carolina, and Pleasanton, California, through Business Wire. It extends the previously announced EDC partnership between the two companies.
According to the companies, bringing their capabilities together is intended to help customers increase trial speed and efficiency, strengthen site centricity, and make better-informed decisions. The stated end goal is helping get life-changing treatments to patients faster. These are the companies’ own expected benefits, and they are forward-looking in nature.
The release adds that all Veeva clinical solutions are also available through IQVIA for sponsors who wish to enable a full Veeva technology stack. At the same time, customers keep the flexibility to choose their own EDC, RTSM, and eCOA technologies, including IQVIA’s own capabilities.
What the IQVIA Veeva Clinical Operations Selection Covers
Four Veeva applications are named in the announcement: CTMS, eTMF, Study Startup, and Site Connect. They have been designated enterprise standards for IQVIA clinical development studies. The release does not disclose a rollout timeline, financial terms, the number of studies affected, or a migration plan, so all of these are listed as “Not disclosed” in the data tables below.
The new selection builds on an existing relationship. The release describes it as an extension of the previously announced EDC partnership. Veeva founder and CEO Peter Gassner described the news as an expansion of the partnership the companies announced last year and of the work they have done together since.
For sponsors, the practical point is choice. A sponsor can use the full Veeva stack through IQVIA, or it can select EDC, RTSM, and eCOA solutions independently. The IQVIA Veeva clinical operations model therefore combines a standardized core of Veeva applications with optional technology choices for customers.
Leadership Perspectives on IQVIA Veeva Clinical Operations Integration
Richard Staub, president of Research and Development Solutions at IQVIA, said the partnership gives clinical teams a more connected way to work, built on “frictionless integration of our respective technologies.” He also stressed that customers keep the flexibility to choose the EDC, RTSM, and eCOA solutions that best meet their needs.
Peter Gassner of Veeva said the companies are committed to supporting “seamless product and services integration” for the benefit of customers. He also tied that commitment to improving access to innovations for patients.
Company Profiles Behind the IQVIA Veeva Clinical Operations Partnership
IQVIA describes itself as a leading global provider of clinical research services, commercial insights, and healthcare intelligence for the life sciences and healthcare industries. Its solutions are powered by IQVIA Connected Intelligence and draw on health data, Healthcare-grade AI, and advanced analytics. The company reports approximately 94,000 employees in over 100 countries. It also states a commitment to responsible AI use and to protecting individual patient privacy.
Veeva describes itself as delivering the industry cloud for life sciences, with applications, agents, data, and consulting. The company serves more than 1,500 customers, from the world’s largest pharmaceutical companies to emerging biotechs. It is a Public Benefit Corporation, which it says means balancing the interests of customers, employees, shareholders, and the industries it serves.
Forward-Looking Statements and Risks Around IQVIA Veeva Clinical Operations
The release includes Veeva forward-looking statements covering its products and services, the partnership with IQVIA, and the expected benefits of both. Veeva states that these are based on current expectations and that actual results could differ materially. It also says it has no obligation to update them.
Veeva points to the risk disclosures in its Form 10-Q for the period ended July 31, 2026, with a summary of risks on pages 33 and 34, and to its subsequent SEC filings. Anyone assessing the IQVIA Veeva clinical operations announcement should read those filings alongside this article.
Announcement Snapshot :
| Data Point | Detail |
|---|---|
| Announcement date | October 13, 2026 |
| Distribution | Business Wire |
| Companies | IQVIA (NYSE: IQV); Veeva Systems (NYSE: VEEV) |
| Locations | Research Triangle Park, N.C.; Pleasanton, Calif. |
| Nature of news | Partnership expansion |
| Prior relationship | Previously announced EDC partnership |
| Financial terms | Not disclosed |
| Rollout timeline | Not disclosed |
| Number of studies affected | Not disclosed |
Applications Selected as Enterprise Standards :
| Application | Vendor | Scope Stated in Release |
|---|---|---|
| Veeva CTMS | Veeva Systems | Enterprise standard across IQVIA clinical development studies |
| Veeva eTMF | Veeva Systems | Enterprise standard across IQVIA clinical development studies |
| Veeva Study Startup | Veeva Systems | Enterprise standard across IQVIA clinical development studies |
| Veeva Site Connect | Veeva Systems | Enterprise standard across IQVIA clinical development studies |
| Veeva EDC | Veeva Systems | Previously announced partnership, extended by this news |
Company Profile Comparison :
| Attribute | IQVIA | Veeva Systems |
|---|---|---|
| Ticker | NYSE: IQV | NYSE: VEEV |
| Self-description | Global provider of clinical research services, commercial insights and healthcare intelligence | Industry cloud for life sciences |
| Employees | Approximately 94,000 | Not disclosed |
| Geographic reach | Over 100 countries | Not disclosed |
| Customers | Not disclosed | More than 1,500 |
| Corporate structure | Not disclosed | Public Benefit Corporation |
| Executive quoted | Richard Staub, President, Research and Development Solutions | Peter Gassner, Founder and CEO |
